This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Molson Coors (TAP) Gains as Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
Molson Coors' (TAP) Q2 results reflect gains from favorable pricing and the U.S. shipment timing, offset by a decline in the contract brewing volumes.
Vital Farms (VITL) Q2 Earnings on the Deck: Key Factors to Note
by Zacks Equity Research
Vital Farms (VITL) is poised for a robust second-quarter performance, driven by its strategic expansion, operational efficiencies and ability to capitalize on market trends.
TreeHouse Foods (THS) Q2 Earnings Beat Estimates, Sales Drop
by Zacks Equity Research
TreeHouse Foods' (THS) Q2 results reflect declines in sales and earnings on lower volumes. Management lowers the upper end of its adjusted EBITDA guidance for 2024.
Medifast (MED) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Medifast's (MED) Q2 results highlight the challenges of poor customer acquisition. However, the company is focusing strategically on medically supported weight loss, indicating potential for growth.
Zacks.com featured highlights include Vital Farms CSW Industrials, Atmos, NiSource and Kirby
by Zacks Equity Research
Vital Farms CSW Industrials, Atmos, NiSource and Kirby have been highlighted in this Screen of The Week article.
J&J Snack Foods (JJSF) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
J&J Snack Foods (JJSF) delivered earnings and revenue surprises of -1.49% and 0.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
5 Low-Leverage Stocks to Buy Amid Disappointing Job Data
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy VITL, CSWI, ATO, NI & KEX.
Inter Parfums (IPAR) Q2 Earnings in the Cards: Things to Note
by Zacks Equity Research
Inter Parfums' (IPAR) second-quarter performance is likely to reflect strong momentum in the fragrance market, supported by robust sales from its new licenses. High SG&A costs are a threat.
Monster Beverage's (MNST) Q2 Earnings Coming Up: Things to Note
by Zacks Equity Research
Monster Beverage's (MNST) second-quarter 2024 results are likely to reflect gains from strength in its energy drinks category and product launches.
B&G Foods' (BGS) Q2 Earnings in the Cards: Factors to Watch
by Zacks Equity Research
B&G Foods' (BGS) Q2 results are likely to reflect the impacts of category-wide challenges across the food industry and high SG&A costs.
Can Molson Coors' (TAP) Strategies Outrun Inflation Woes in Q2?
by Zacks Equity Research
Molson Coors' (TAP) strategic investments and premiumization efforts drive robust growth amid industry challenges and inflationary pressures. Let us see how the Q2 performance is likely to have been.
AB InBev (BUD) Tops on Q2 Earnings & Revenues on Robust Demand
by Zacks Equity Research
AB InBev's (BUD) Q2 results reflect strong consumer demand for its megabrands, double-digit organic EBITDA growth and continued optimization of its business.
Post Holdings (POST) Tops Q3 Earnings, Raises FY24 Outlook
by Zacks Equity Research
Post Holdings (POST) fiscal third-quarter results reflect sales growth in Post Consumer Brands and Weetabix, counterbalanced by declines in the Foodservice and Refrigerated Retail segments.
Implied Volatility Surging for Vital Farms (VITL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Vital Farms (VITL) stock based on the movements in the options market lately.
Clorox (CLX) Q4 Earnings Beat Estimates, Gross Margin Expands
by Zacks Equity Research
Clorox's (CLX) fiscal 2025 gross margin is expected to improve by around 100 basis points, driven by comprehensive margin management efforts.
Mondelez (MDLZ) Q2 Earnings Beat, Organic Revenues Up 2.5%
by Zacks Equity Research
Mondelez (MDLZ) posts soft sales in second-quarter 2024, whereas organic revenues grow 2.5%. Strong pricing and cost management actions also fuel bottom-line growth.
Altria's (MO) Q2 Earnings Lag Estimates, Cigarette Volumes Drop
by Zacks Equity Research
Altria's (MO) second-quarter 2024 results reflect strong pricing, while cigarette shipment volumes remain soft. Management narrows the adjusted EPS view for 2024.
Clorox (CLX) Raises Dividend: What it Means for Investors
by Zacks Equity Research
Clorox's (CLX) strategy of incremental dividend growth not only bolsters shareholder income but also reinforces investor confidence in the company.
Diageo (DEO) FY24 Earnings & Sales Decline Y/Y on Soft Volume
by Zacks Equity Research
Diageo's (DEO) FY24 results reflect the impacts of soft volume particularly in LAC and North America, which hurt organic sales. Soft operating profit and higher costs hurt the bottom line.
Archer Daniels (ADM) Q2 Earnings & Revenues Miss, Down Y/Y
by Zacks Equity Research
Archer Daniels (ADM) reports lower revenues year over year in second-quarter 2024 owing to a decline in sales across its segments.
Procter & Gamble (PG) Q4 Earnings Beat, Stock Down on Sales Miss
by Zacks Equity Research
Procter & Gamble's (PG) Q4 earnings reflect gains from improved volume and pricing, offset by adverse currency rates and higher costs, which impact its operating margin.
Sysco (SYY) Shares Rise on Q4 Earnings Beat & Revenue Growth
by Zacks Equity Research
Sysco's (SYY) fourth-quarter fiscal 2024 results reflect improved earnings and revenues. The company witnesses positive operating leverage for the seventh consecutive time.
Sprouts Farmers (SFM) Gains as Q2 Earnings Beat & Comps Impress
by Zacks Equity Research
Sprouts Farmers (SFM) anticipates the gross margin to improve in the second half, in line with the first-half margin expansion.
Vital Farms (VITL) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw Vital Farms (VITL) settling at $36.82, representing a +1.94% change from its previous close.
Here's Why Vital Farms (VITL) is Poised for a Turnaround After Losing -22.77% in 4 Weeks
by Zacks Equity Research
Vital Farms (VITL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.